Compare Novo Nordisk A/S (NVO) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs United States Natural Gas Fund — how do they compare? Novo Nordisk A/S trades at $44.84 (market cap $198.57B), while United States Natural Gas Fund trades at $10.05. The key difference: Novo Nordisk A/S pays a 4.03% dividend while United States Natural Gas Fund pays none, and Novo Nordisk A/S is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| NVO | UNG | |
|---|---|---|
Market Cap | $198.57B | — |
Sector | Health | Commodities - Energy |
52-Week High | $63.98 | $16.90 |
52-Week Low | $35.29 | $9.63 |
Enterprise Value | $213.37B | — |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
UNG trades at $10.46, down 0.95% today, with a bearish technical signal from moving averages and neutral oscillators. Support and resistance cluster tightly around $10-$11. The fund tracks natural gas futures, facing headwinds from high production and storage levels, while demand forecasts remain strong for 2026-2027 per EIA (2026-09-09).
Outlook hinges on natural gas price volatility; upside exists if demand outpaces supply, but risks include oversupply and geopolitical impacts. Investors face contango roll costs in futures-based ETFs, contrasting with equity alternatives like FCG.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
